Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | USP2 | O75604 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116277 | 1.00 | MAPT (0.49) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL3127325 | 1.00 | MAPT (0.49) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL25923178 | 0.98 | MAPT (0.46) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL3117140 | 0.98 | MAPT (0.46) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL3120777 | 0.92 | ALDH1A1 (0.40) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL3116666 | 0.85 | — | — | |
| SCHEMBL1524396 | 0.84 | MAPT (0.50) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL7560013 | 0.84 | MAPT (0.50) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL723135 | 0.84 | MAPT (0.50) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL7558719 | 0.84 | MAPT (0.50) | MAPTALDH1A1USP2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | MAPT 4366/4885ALDH1A1 1706/4885USP2 2287/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | MAPT 3535/4885ALDH1A1 2694/4885USP2 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.